• Technology Transfer Tactics will be offering a webinar entitled "Patenting Machine Learning and AI Innovations: Strengthen Your Claims to Avoid Rejection" on October 16, 2018 from 1:00 to 2:00 pm (ET).  Gregory Rabin of Schwegman, Lundberg & Woessner will address the following topics:

    • Definition of machine learning and types of machine learning
    • Drafting claims for machine learning technology (simple non-real-life example)
    • Real-life example that overcame a patentable subject matter (35 U.S.C. § 101) rejection
    • Patent Office Art Units for machine learning inventions
    • Berkheimer v. HP and its departure from Alice
    • Patent Office Berkheimer Memorandum — defining "well-understood, routine, conventional activity"
    • Suggestions for improving invention disclosures and claims

    The registration fee for the webinar is $197.  Those interested in registering for the webinar, can do so here.

    Technology Transfer Tactics

  • By Donald Zuhn —

    USPTO SealOn Monday, the U.S. Patent and Trademark Office announced the implementation of a new authentication method for signing into the EFS-Web and Private PAIR.  According to the Office, the new method is safer and simpler, grants access to multiple USPTO systems with one consolidated sign-in, and eliminates the need to share credentials by providing practitioners and their support staff with their own USPTO.gov accounts.  The new method also helps to resolve browser compatibility issues, and will provide users with access to the EFS-Web and Private PAIR until the full release of Patent Center, which is scheduled to replace the EFS-Web and Private PAIR, in 2020.

    The Office also announced the release of a migration tool, which allows existing PKI digital certificate holders to link their USPTO.gov accounts to their current PKI digital certificates.  To migrate an existing PKI digital certificate, users must have a USPTO.gov account.  Users who need to create a USPTO.gov account can do so by following the steps under the "Create a USPTO.gov Account" tab at the Office's authentication change webpage.  Once a USPTO.gov account has been created, users can follow the steps under the "Migrate your PKI Certificate" tab at the Office's authentication change webpage (or refer to the Guide for Migration) to link that account to their PKI certificate.  The Office notes that users should allow 1–2 business days after the migration steps are finished for the migration process to be completed.  Once the process is completed, users will be able to sign into the EFS-Web or Private PAIR using their USPTO.gov account.  Users should use the following new links to sign into the EFS-Web or Private PAIR using their USPRTO.gov accounts:

    EFS-Web:
    https://efs-my.uspto.gov/EFSWebUIRegistered/EFSWebRegistered

    Private PAIR:
    https://ppair-my.uspto.gov/pair/PrivatePair

    Additional information regarding the new authentication process can be found in the Office's Patent Electronic System Access Document.  This resource includes information about USPTO.gov accounts; two-step authentication; signing in and signing out from USPTO systems; Patent Electronic Access roles for practitioners, support staff, and inventors; suspension of accounts; authorization; authentication steps; the sponsorship process (by which practitioners can grant or remove sponsorship for support staff individuals to work under their direction and control); and the Office's verification policy and identity proofing of sponsored support staff.  With respect to identity proofing, the Office notes that "[e]ach practitioner will be responsible for verifying the identity of the person using any sponsored support Staff account."

    Practitioners are cautioned that migration to link USPTO.gov accounts to PKI certificates should be completed by the end of October, sponsorship of support staff should be completed by the end of November, and that PKI certificates are scheduled to be retired in December.  The Office notes that the Sponsorship Tool will not be available until November, so support staff should continue to sign into the EFS-Web and Private PAIR using PKI certificates until November.

    Users requiting assistance to create a USPTO.gov account should call the USPTO Contact Center (UCC) at 800-786-9199.  Users requiring assistance with migration should contact the Patent Electronic Business Center at ebc@uspto.gov or 866-217-9197.  The Office will also be offering several informational sessions on authentication changes; a schedule of upcoming sessions can be found at the "Information sessions" tab at the Office's authentication change webpage.  A list of Frequently Asked Questions (FAQs) about the authentication change for EFS-Web and Private PAIR can be found here.

  • By David Puleo* and Anthony D. Sabatelli** —

    FDATypically, we think of patents as the main tool that allows for product exclusivity in the pharmaceutical industry.  However, exclusivity has a regulatory component.  For example, a new drug product cannot be marketed until it has undergone review and approval by the U.S. Food and Drug Administration (FDA) or other foreign counterpart.  Probably the most familiar regulatory exclusivity is the five years given upon approval of a new drug application (NDA) during which no generic drug application can be filed.[1]  This regulatory exclusivity is a valuable asset, so much so in fact that it is often desirable to accelerate the drug approval process.  An untapped asset that has arisen out of this framework is the priority review voucher (PRV).  A helpful summary on PRVs was recently published in a piece from the Regulatory Affairs Professional Society.

    PRVs were first proposed in 2006 by faculty at Duke University to incentivize the development of drug therapies, specifically citing the unmet medical need for treatments against tropical diseases.[2]  One year later, the FDA implemented the Priority Review Voucher Program, which allows for expedited review of those drugs treating rare or unmet diseases.  The first program, which was created under the FDA Amendments Act of 2007, encouraged development of treatments for disease on the FDA list of tropical diseases, which includes tuberculosis, malaria, and cholera, to name a few.  The FDA also has PRV programs for Rare Pediatric Diseases (RPD) as well as for Medical Countermeasures.  Interestingly, these vouchers can either be used by the company that originally purchased them or can be re-sold to other companies and, thus, are seen as a valuable asset.  The first PRV re-sold for $67M in 2014; the most expensive was sold by United Therapeutics (UT) to AbbVie for $350M.  These prices are dizzying, considering that the FDA fees for the initial drug application filers are just north of $2M.  Despite this, vouchers have become coveted property.

    However, it appears that the value of PRVs has been declining in recent years.  Recently, Kyowa Hakko Kirin and partner Ultragenyx sold an RPD PRV to an undisclosed party for for $80.6 million, 3-4 fold less than the aforementioned UT-AbbVie deal.  However, it is not readily apparent why the value is decreasing.  One reason could be that the FDA has been issuing an increased number of PRVs.  Lawmakers see the added value in how PRVs drive innovation and treatments for unmet diseases; their opinions could have contributed to this trend.  It is uncertain whether this trend will continue.  Nonetheless, PRVs are an important part of a company's portfolio and are still a valuable bargaining chip and exclusivity asset in the tool box of the pharmaceutical company.

    [1] See 21 U.S.C. § 355(c)(3)(E)(ii) of this section of the U.S. Code relating to New Drugs.  The situation is more complex and other regulatory provisions apply, but the point being made is that the FDA provides for various exclusivity periods for small molecule drugs.  Analogous periods of exclusivity are provided under provisions for the Regulation of Biological Products at 42 U.S.C. § 262.

    [2] See the seminal paper proposing PRVs can be found here.

    * David Puleo is Technology Specialist with Dilworth IP
    ** Dr. Sabatelli is a Partner with Dilworth IP

  • By Kevin E. Noonan —

    Ulrich (Uli) Laemmli, an illustrious professor of biochemistry and molecular biology, developer of SDS (sodium dodecyl sulfate)-polyacrylamide electrophoresis (PAGE) for separating proteins, and responsible for identifying the "scaffold" structure of human chromosomes, was fond of saying (when he was a professor at Princeton) that in biological research it was helpful (if not essential) to "look for the mutant."  Difficulties in following this advice productively include the (low) frequency with which mutants arise, the fact that most such mutants lose or compromise the function(s) of the encoded proteins, and that conventional methods for producing mutants are as likely as not to be lethal to cells (either due to mutants of the protein of interest or other proteins that are mutated in passing).  So-called "targeted" mutations produced, in its most au courant version, by CRISPR-Cas9 (wherein CRISPR is an acronym for Clustered Regularly lnterspaced Short Palindromic Repeats) require knowledge of the site to be mutagenized and hence comprise only a limited subset of targets for productive mutagenesis.

    Figure 1
    A group of researchers* from Berkeley have used a modified version of Cas9 (nCas9, bearing a D10A mutation that produces "nicks" in target DNA) to produce a system they term EvolvR for dramatically (7,700,000-fold) increasing in vivo mutagenesis, as reported in the scientific journal Nature in a Letter entitled "CRISPR-guided DNA polymerases enable diversification of all nucleotides in a tunable window."  This is illustrated in E. coli bacteria for producing cells resistant to the antibiotic streptomycin.  The modified nCas9 is fused to the amino terminus of a fidelity-reduced variant (D424A, I709N, A759R) of E. coli DNA polymerase I.  The plasmid encoding this construct also encoded a guide DNA (gDNA) to target a second plasmid containing a homologous gene sequence.  These model experiments showed mutations (of all expected types) arising within a 17 nucleotide window 3' of the nick site, consistent according to these authors with the known 15-20 nucleotide processivity of the polymerase, as illustrated below.  There were also a low frequency of 5' mutations that the authors speculated may have been due to the polymerase's 3'-5' exonuclease activity.  Also tested was a reversion assay, wherein the target plasmid encoded a streptomycin resistance gene bearing a nonsense mutation.  Against a measured background mutation rate of 10-10 mutations/nucleotide/ generation, consistent with E. coli mutation rates, introducing the EvolvR plasmid into these cells "markedly increased the mutation rate at the targeted locus 24,500-fold over the wild type while increasing the global mutation rate 120-fold over the wild type," which the authors state is similar to other mutagenesis methods used in E. coli.

    Figure 2
    Mutation rates using this system were further enhanced by making additional mutations in nCas-9 (K848A, K1003A, R1060A); these mutations had been suggested in the art to "lower the non-specific DNA affinity of Cas-9."  These plasmids "increased the global mutation rate 223-fold compared to wild-type cells (1.9–fold greater than nCas9–PolI3M), yet elevated the mutation rate at the targeted locus by 212,000-fold (8.7-fold greater than nCas9–PolI3M)."  The mutagenesis rate was further increased to the maximum reported (7,700,000-fold) by further modifications (D424, I709N, F742Y, A759R, and P796H) to the polymerase portion of the fusion protein.  Alternative polymerases (from the bacteriophage Phi129) did not achieve this high a mutation rate, nor was inserting the thioreductase-binding domain of bacteriophage T7 DNA polymerase into the PolI sequence as effective (although this change did increase the reach of mutation rate in the target DNA).  Other refinements included removing internal ribosome binding sites in the PolI sequence to reduce (4.14-fold) "off-target" mutagenesis.

    The authors also report the ability to target separate DNA target sequences, although they note that when those targets are within 110 bp of each other, the nicking activity should be directed to the same strand to avoid lethality.

    The paper ends with the following hopes for future applications of the technology:

    EvolvR offers the first example of continuous targeted diversification of all nucleotides at user-defined loci, which will be useful for evolving protein structure and function, mapping protein–protein and protein–drug interactions, investigating the non-coding genome, engineering industrially relevant microbes and tracking the lineage of cell populations that cannot tolerate double-stranded breaks.  As a guiding principle for using this tool, our data suggest that 1µl saturated E. coli culture expressing enCas9–PolI3M–TBD for 16h contains all single substitutions in the 60-nucleotide window with more than tenfold coverage.  Future work towards adapting EvolvR for use in cells possessing low transformation efficiency, as well as increasing the mutation rate and window length of EvolvR mutagenesis, would enable new forward genetic applications.

    *Shakked O. Halperin, Connor J. Tou, Eric B. Wong, Cyrus Modavi, David V. Schaffer & John E. Dueber

  • By Michael Borella —

    Federal Circuit SealAlmost two years ago, we covered a dispute in the Southern District of New York (which began in the Eastern District of Texas) involving plaintiff AlphaCap, a non-practicing entity that aggressively asserted its patents against a number of targets, including Gust.  In short, when Gust didn't quickly settle, AlphaCap offered to dismiss its claims.  But Gust wanted AlphaCap to pay its attorneys' fees or assign AlphaCap the patents.  After some back-and-forth between the parties, the District Court dismissed the case but awarded Gust attorneys' fees under 35 U.S.C. § 285.  Gutride Safier LLP, attorneys for AlphaCap, were held jointly and severally liable for these fees and costs under 28 U.S.C. § 1927.

    Notably, the District Court stated that the case was "exceptional" under § 285 because the Supreme Court's Alice Corp. v. CLS Bank Int'l opinion "gave AlphaCap clear notice that the AlphaCap Patents could not survive scrutiny under 35 U.S.C. § 101."  The basis of this conclusion was that "the claims were directed to crowdfunding, a fundamental economic concept and way of organizing human activity, and that this was an abstract idea."  The District Court further held that "the claims did not include an inventive concept sufficient to render the abstract ideas patent eligible under Alice."

    Regarding § 1927, the District Court found Gutride to have acted unreasonably and in bad faith during the dispute, because it was unwilling to recommend settlement "despite knowing that Alice doomed the claims and stating that the case was 'not worth litigating'."

    Gutride brought this appeal to the Federal Circuit solely on the issue of its liability for the attorneys' fees.  Judge Linn wrote the opinion of the Court and was joined by Judge Hughes.  Judge Wallach dissented.

    The Majority Opinion

    28 U.S.C. § 1927 states:

    Any attorney or other person admitted to conduct cases in any court of the United States or any Territory thereof who so multiplies the proceedings in any case unreasonably and vexatiously may be required by the court to satisfy personally the excess costs, expenses, and attorneys' fees reasonably incurred because of such conduct.

    Applying the law of the Second Circuit, a successful motion under § 1927 requires that: (i) the case was "entirely without color", and (ii) was "brought in bad faith—that is, motivated by improper purposes such as harassment or delay."  These determinations require a court to "provide a high degree of specificity in the factual findings."

    Addressing the first prong, the Gutride referenced the "unsettled state of the law following the decision in Alice" as evidence that its case had color.  Gust responded by contending that "the § 101 law post-Alice was settled, because all cases dealing with abstract ideas in patents cited the two-step Alice framework," and that "the claims here were not even questionably patent eligible."

    The Federal Circuit agreed with Gutride, noting that there was a "relative paucity of § 101 cases that were decided by this court between Alice and AlphaCap's complaint in Texas."  Indeed, several of the Federal Circuit's own cases from this time period "recognized the uncertainty in the application of Alice."  The Court further observed that "[w]hen the applicable law is unsettled, attorneys may not be sanctioned merely for making reasonable arguments for interpreting the law."  Instead, "it is particularly important to allow attorneys the latitude necessary to challenge and thus solidify the legal rules without the chill of direct economic sanctions."  Also, according to the Court, Gutride made a colorable argument that the claims met the requirements of § 101 due to being analogous to DDR Holdings, LLC v. Hotels.com L.P., while Gust's analogy between the claims and those found ineligible in another Southern District of New York case was unpersuasive.  Finally, the Court strongly disagreed with Gust that the mere existence of the two-step Alice framework implied that § 101 law was settled, and found the District Court's patent-eligibility analysis to be conclusory.

    When applying the second prong, the District Court concluded that Gutride's actions constituted bad faith based on three grounds: (i) "Gutride knew that AlphaCap's patents were not patent eligible after Alice, and initiated the litigation anyway to extract a nuisance settlement"; (ii) Gutride's opposition to transferring the case to the Southern District of New York; and (iii) "Gutride's failure to end the case through settlement, dismissal, or a covenant not to sue."

    Regarding Gutride's alleged knowledge that the patents were not eligible, the District Court put a fair amount of weight on Gutride's statement that "the case is 'not worth litigating'."  But the Federal Circuit viewed this statement as a negotiating position, noting that "[i]n the context of advocating for settlement with the opposing party to settle, this is an inoffensive assertion that the calculus favors settlement, not an admission that the patents were invalid."

    With respect to the nuisance settlement, the Federal Circuit was more sympathetic.  It acknowledged that "AlphaCap bears relatively little risk and cost in filing its infringement actions, as compared with the relatively high costs incurred by defendants to defend the lawsuit."  Thus, by "encouraging quick settlements at values far below the cost of defending an infringement action on the merits, AlphaCap was able to obtain not insignificant revenues without having to test the merits of its position."  Nonetheless, the Court found that "Rule 11, with its procedural safeguards, already addresses attorneys' complicity in the filing of frivolous and improper litigation" and that "§ 1927 only applies to actions that result in unreasonable and vexatious multiplication of proceedings."  Consequently, the Court ruled with Gutride on this issue.

    The Court also sided with Gutride regarding its resistance to the transfer.  Driving this conclusion was the fact that the Eastern District of Texas was a proper venue, that Gust had agreed to venue discovery, and because "at least some third-party users were found to reside in the Eastern District of Texas."  Supporting these points, the Court observed that "an attorney need not bring a case in the most convenient forum, but only a proper forum."

    Finally, the Court also agreed with Gutride that failure to settle is not evidence of bad faith.  Notably, "[t]he decision to settle or grant a covenant not to sue is wholly committed to clients, not their attorneys."  Thus, Gutride could not be held liable for its client's decision.

    For these reasons, the Court sided with Gutride and reversed the award of fees under § 1927.

    Judge Wallach's Dissent

    Writing in dissent, Judge Wallach faulted the majority for reversing the District Court.  A significant part of Judge Wallach's beef was based on the § 101 issues.  He disagreed that the law regarding patent-eligibility was unsettled, stating it was that "the framework with which we have consistently assessed patent eligibility under § 101 since its rendering."

    Attacking the claims, Judge Wallach found them "directed to data organization and use of customizable profiles to facilitate patronage," which in his view were clearly abstract ideas.  While the majority found that § 101 jurisprudence as a whole was evolving, Judge Wallach stated that no claims similar to AlphaCap's were determined eligible by the Federal Circuit during the litigation.  In his words:

    The Asserted Claims merely recite a series of steps for storing and organizing investment data that could all be performed by humans without a computer, and Gutride's attempt to assert otherwise was frivolous given that the abstract idea here is not meaningfully different from the ideas found to be abstract in other cases before the Supreme Court and our court involving methods of organizing human activity.

    He also found additional elements lacking an inventive concept under Alice, as they were all involving conventional and generic terms.  Thus, with respect to § 101 as a whole, Judge Wallach concluded that "[t]he Patents-in-Suit clearly do not fall in that interstitial area where doubt may reasonably exist."  Judge Wallach was silent regarding the fact that he and the majority coming to two different conclusions when applying Alice to the claims suggests that the law surrounding § 101 is still unsettled.

    Determining that the District Court did not abuse its discretion in finding that AlphaCap's case lacked a colorable basis, Judge Wallach moved on to bad faith.

    Particularly, he found no flaw in the District Court's assessment of Gutride being "motivated by improper purposes such as harassment or delay."  He did not address the majority's position that Rule 11 controlled, and instead found "we must holistically consider Gutride's entire course of conduct in order to determine if it acted in bad faith by delaying dismissal of its suit, when it had knowledge of the suit's frivolous nature."  Further, he found that the "not worth litigating" statement occurred early enough in the case that Gutride could have pushed to settle the dispute much earlier.  Judge Wallach saw this as a "bad faith attempt to multiply the proceedings."

    Turning to venue, Judge Wallach pointed to evidence that Gutride claimed that Gust had ties to the Eastern District of Texas, could not establish that said ties existed, and only after discovery was able to show that Gust had some users in the district.  This, apparently, was enough for Gutride to fail the bad faith sniff test.

    Consequently, Judge Wallach would have affirmed the District Court.

    Analysis

    Regarding overly-aggressive litigation and the venue issue, Gutride may have indeed pushed the envelope.  On whether its conduct rises to the level of bad faith, the majority was probably correct to err on the side of caution.  Judge Wallach, on the other hand, gave more deference to the District Court.

    But the majority was clearly correct to conclude that § 101 jurisprudence was too murky during the time of the litigation (early 2015 – late 2016) to conclude that AlphaCap's case was without color.

    In 2015, the Federal Circuit found no claims patent-eligible under § 101.  But this does not imply that all business method and software claims involving data manipulation were categorically ineligible — it merely suggests that the Court did not hear a case with claims that passed the test.  Also, not long prior to this time frame, there were multiple federal judges commenting on the record that Alice was hard to apply in practice.  Judge Wu of the U.S. District Court for the Central District of California criticized Alice for setting forth an "I know it when I see it" test.  Judge Pfaelzer, a colleague of Judge Wu, wrote that the Supreme Court's patent-eligibility cases "often confuse more than they clarify [and] appear to contradict each other on important issues."

    More recently, Judge Wallach's Federal Circuit colleague, Judge Plager, wrote that the post-Alice §101 inquiry "renders it near impossible to know with any certainty whether the invention is or is not patent eligible."  And these are just a few examples of judicial confusion.  There are more.  The law was not settled during the case, and is even less settled now.

    Thus, it is hard to agree with Judge Wallach.  Moreover, with a § 101 challenge being routinely raised against any asserted software or business method patent, the impact of penalizing plaintiffs and their attorneys for exercising such a patent would be to shut off nearly all software or business method litigation.

    That is not to say that bad actors should not be punished.  But contending that § 101 is settled law to do so is absurd.  The only thing settled about patent-eligibility in the last four years is that it is unsettled.

    Gust, Inc. v. AlphaCap Ventures, LLC (Fed. Cir. 2018)
    Panel: Circuit Judges Wallach, Linn, and Hughes
    Opinion by Circuit Judge Linn; dissenting opinion by Circuit Judge Wallach

  • CalendarOctober 2, 2018 – "Advice of Counsel Defense in Patent Litigation and Protecting Attorney-Client Privilege — Limiting Scope of Discovery, Safeguarding Confidential Communications and Information" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 2-3, 2018 – Paragraph IV Disputes master symposium (American Conference Institute) – Chicago, IL

    October 3, 2018 – "2018 Bench & Bar® in Dialogue: Federal Circuit Court Visit!" (Federal Circuit Bar Association) – 2:00 pm to 9:00 pm (CT), Chicago, IL

    October 4, 2018 – "Patent Litigation in Japan and Germany," German Patent and Trade Mark Office, Munich, Germany

    October 4, 2018 – "Biosimilars in the Antitrust Spotlight: Patent Litigation and Settlement" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    October 11, 2018 – "Patent Term Adjustments and Extensions: Leveraging Recent Decisions and USPTO Rule Changes" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 12, 2018 – "Standard Essential Patents: What Every IP Attorney and In-house Counsel Should Know" (John Marshall Law School Center for Intellectual Property, Information & Privacy Law) – 9:00 am to 4:30 pm, Chicago, IL

    October 16, 2018 – "Negotiating IP Rights in Industry Sponsored Research Agreements — Structuring Ownership, Licensing, Assignment, Confidentiality, Publication and Use Provisions" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 16-18, 2018 – PCT Seminar (Oppedahl Patent Law Firm LLC) – Redwood City, CA

    October 23, 2018 – "The State of 'Printed Publication' Prior Art Case Law: Practical Considerations for Patent Holders and Patent Challengers" (Strafford) – 1:00 to 2:30 pm (EDT)

    October 24, 2018 – Biopharma Patent Law (McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs) – 9:30 am to 1:00 pm, Cambridge, MA

    October 24, 2018 – "Preparing 'Diagnose & Treat' Patent Claims to be Valid and Enforceable" (Technology Transfer Tactics) – 1:00 to 2:00 pm (ET)

    October 24, 2018 – "Crisis Management for IP Lawyers & Their Clients — Trade Secrets and Reputation Risk Management" (Intellectual Property Law Association of Chicago Trade Secret and Unfair Competition Committee) – 3:00 to 4:00 pm (CT), Chicago, IL

  • Strafford #1Strafford will be offering a webinar entitled "The State of 'Printed Publication' Prior Art Case Law: Practical Considerations for Patent Holders and Patent Challengers" on October 23, 2018 from 1:00 to 2:30 pm (EDT).  Jason S. Angell of Hopkins & Carley and Emily J. Greb of Perkins Coie will provide an in-depth discussion for counsel on the history and current state of the law regarding when a non-patent prior art reference qualifies as a "printed publication" for purposes of an invalidity challenge; will discuss recent Federal Circuit, district court, and PTAB decisions and the emerging guidance for assessing whether a reference is sufficiently "publicly accessible" to be considered a "printed publication" under 35 U.S.C. § 102; and will also review strategic approaches for demonstrating or disputing that a reference qualifies as printed publication prior art.  The webinar will review the following issues:

    • How is the court evaluating public accessibility standards and evidence? How are these decisions influencing federal courts and the PTAB?
    • What lessons can patent counsel draw from recent decisions when assessing print publications as prior art?
    • What role to “confidentiality expectations” or restrictions on dissemination play in the public accessibility analysis?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • Technology Transfer Tactics will be offering a webinar entitled "Preparing 'Diagnose & Treat' Patent Claims to be Valid and Enforceable" on October 24, 2018 from 1:00 to 2:00 pm (ET).  Charles R. Macedo, Alan D. Miller, and Brian J. Amos will address the following topics:

    • State of the law on patent-eligibility and divided infringement
    • Review of recent cases involving single and two-actor method claims, including:
        – Cleveland Clinic Foundation v. True Health Diagnostics LLC
        – Eli Lilly & Co. v. Teva Parenteral Medicines Inc.
        – Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals
    • Sample form of claims that straddle patent-eligibility and divided infringement concerns
    • USPTO guidance and examples
    • Strategies for increasing likelihood of obtaining meaningful patent protection from the USPTO
    • Dealing with concerns of potential licensees

    The registration fee for the webinar is $197.  Those interested in registering for the webinar, can do so here.

    Technology Transfer Tactics

  • IPLACThe Intellectual Property Law Association of Chicago (IPLAC) Trade Secret and Unfair Competition Committee will be presenting a presentation by Bruce Hennes of Hennes Communications entitled "Crisis Management for IP Lawyers & Their Clients — Trade Secrets and Reputation Risk Management" on October 24, 2018 from 3:00 to 4:00 pm (CT) at the Union League Club in Chicago, IL.  The presentation will focus on a highly-strategic approach to crisis management and crisis communications for a wide variety of situations, offering methods to establish and maintain "control of the message," enabling attorneys to help their firms and clients move messages forward or mount a defense against an outraged public, unhappy customers or a sudden press onslaught.

    The registration fee for the presentation is $20 (IPLAC members), $5 (students), or $25 (non-members).  Those interested in registering for event can do so here.

  • Federal Circuit Distinguishes Obviousness between Apparatus and Method Claims

    By Aaron Gin –

    Federal Circuit SealOn September 13, 2018, the Federal Circuit affirmed three final written decisions of the U.S. Patent Trial and Appeal Board that held unpatentable various claims of U.S. Patent No. 6,091,940, owned by ParkerVision.  The '940 patent, entitled "Method and System for Frequency Up-Conversion," relates to the frequency conversion of low-frequency baseband signals to higher-frequency (e.g., radio frequency or RF) signals.

    Qualcomm filed three petitions for inter partes review challenging the '940 patent.  The PTAB's (and later the Federal Circuit's) analysis split along whether the claims were apparatus or method claims.  Claim 21 was representative of the apparatus at issue:

    21.  An apparatus for frequency up-conversion, comprising:
        a pulse shaping module to receive an oscillating signal and to output a shaped string of pulses that is a function of said oscillating signal;
        a switch module to receive said shaped string of pulses and a bias signal, wherein said shaped string of pulses causes said switch module to gate said bias signal and thereby generate a periodic signal having a plurality of harmonics, said bias signal being a function of an information signal, said periodic signal having an amplitude that is a function of said bias signal; and
        a filter coupled to said switch module to isolate one or more desired harmonics of said plurality of harmonics.

    Claim 25 was representative of the method at issue:

    25.  A method of communicating, comprising the steps of:
        (1) shaping an oscillating signal to create a string of pulses that is a function of said oscillating signal;
        (2) gating a reference signal at a rate that is a function of said string of pulses to create a periodic signal having a plurality of harmonics, said reference signal being a function of an information signal, and at least one of said plurality of harmonics being a desired harmonic; and
        (3) outputting said periodic signal, said periodic signal having an amplitude that is a function of said reference signal.

    In two of the three petitions, Qualcomm asserted that the challenged apparatus and method claims would have been obvious in view of three references — Nozawa, Philips, and Maas (the Nozawa IPRs).  In the third petition, Qualcomm asserted that the apparatus claims would have been obvious in view of Maas and two additional references — Krauss and Ariie (the Ariie IPR).  The Board instituted review with regard to all three petitions.

    ParkerVision filed patent owner responses.  With regard to the Nozawa IPRs, the patent owner argued that the petitions failed to identify any teaching that expressly disclosed a periodic signal containing "integer multiples" of any frequency, as required by the claims' "harmonics" limitation.  ParkerVision also argued that Qualcomm's own expert had described a periodic signal with only one integer-multiple harmonic, as opposed to the claimed "plurality" of such harmonics.  Finally, the patent owner argued that the Ariie IPR failed to prove how Ariie's field effect transistor is a "switch" and did not describe how Ariie's oscillating signal "gates" that switch, as required by the claims.

    Qualcomm filed reply briefs that argued, among other points, that basic math confirms that for many input frequencies, Nozawa's mixer will generate the required "integer multiple" harmonics.  Furthermore, petitioner argued that persons of ordinary skill in the art would have recognized that Krauss' rectangular waveform would have caused Ariie's FET to act as a gate or switch.

    On March 7, 2017, the Board issued three final decisions, each finding that the challenged apparatus claims would have been obvious.  However, with regard to the Nozawa IPRs, the Board found that Qualcomm had impermissibly changed its theory of unpatentability as to the method claims.  As such, the Board found that Qualcomm did not provide any evidence as to why a person of ordinary skill would have selected operating conditions that would cause Nozawa to generate a plurality of integer-multiple harmonics.  However, the Board agreed with Qualcomm as to the Ariie IPR, stating that the rectangular wave of Krauss would drive the Ariie FET as a switch.

    ParkerVision appealed, arguing that the Board erred in holding the apparatus claims unpatentable.  Qualcomm also cross-appealed, arguing that the Board erred in upholding the patentability of the method claims.

    On appeal, ParkerVision argued that the Board erred by basing its patentability decisions on theories and evidence that Qualcomm did not present in its petitions.  Also, ParkerVision contended that the Board's unpatentability determination as to the apparatus claims was based on an untimely and erroneous construction of the underlying claim language.

    The panel, which included Judges O'Malley, Reyna, and Taranto, was unmoved by ParkerVision's position, saying that it was undisputed that Nozawa's device would necessarily product a periodic signal containing integer multiples of the fundamental frequency under some, albeit not all, conditions.  The Board recalled Hewlett Packard Co. v. Bausch & Lomb Inc., 909 F.2d 1464, 1468 (Fed. Cir. 1990), stating, "[a]pparatus claims cover what a device is, not what a device does."  Specifically, with regard to the apparatus claims, Judge O'Malley, writing for the Panel, stated:

    A prior art reference may anticipate or render obvious an apparatus claim – depending on the claim language – if the reference discloses an apparatus that is reasonably capable of operating so as to meet the claim limitations, even if it does not meet the claim limitations in all modes of operation.

    The panel treated the method claims of the '940 patent in a wholly different manner, stating that Qualcomm failed to "present evidence and argument that a person of ordinary skill would have been motivated to operate Nozawa in a manner that satisfied the 'plurality of harmonics' limitation."  Furthermore, Qualcomm did not advance any position whether Nozawa's device would actually output a periodic signal with a plurality of integer-multiple harmonics.  Namely, the panel reiterated InTouch Techs. Inc. v. VGO Commc'ns, Inc., 751 F.3d 1327, 1346-1347 (Fed. Cir. 2014), that parties seeking to invalidate method patents must show that a skilled artisan would have been motivated to combine the teachings of the prior art references to achieve the claimed invention, and that the skilled artisan would have had a reasonable expectation of success in doing so.  Instead, the panel wrote, "Qualcomm's petitions and accompanying expert testimony solely concerned whether the fundamental frequency itself is included in the meaning of 'harmonics.'"

    In other words, with respect to apparatus claims, the Federal Circuit stated that if a prior art reference discloses an apparatus that is reasonably capable of operating as claimed, that reference could anticipate or render obvious the claims at issue.  Additionally, when considering method claims, a reference is properly asserted, under 35 U.S.C. §§ 102 & 103, when there is a clear motivation to combine the references and a demonstrated expectation of success by a skilled artisan.

    ParkerVision, Inc. v. Qualcomm Inc. (Fed. Cir. 2018)
    Panel: Circuit Judges O'Malley, Reyna, and Taranto
    Opinion by Circuit Judge O'Malley